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OBJECTIVES The study sought to determine the incidence and predictors of late total occlusion (LTO,
.30 days) in-patients with in-stent restenosis who were treated with intracoronary radiation.
BACKGROUND Intracoronary radiation both with beta and gamma emitters has been shown to reduce
recurrent in-stent restenosis.
METHODS We reviewed the records of 473 patients who presented with in-stent restenosis and who were
enrolled in various radiation protocols, whether randomized to placebo versus radiation or
entered into registries. There were 165 placebo and 308 radiated patients, including both
gamma and beta emitters. Maximum dose to the vessel wall was 30 to 55 Gy. Following
radiation, all patients received antiplatelet therapy with aspirin and either ticlopidine or
clopidogrel for one month. All patients completed at least six months of angiographic
follow-up.
RESULTS The LTO was documented in 28 patients (9.1%) from the irradiated group versus 2 placebo
patients (1.2%), p , 0.0001. The LTO rates were similar across studies and emitters. In the
irradiated group, LTO presented as acute myocardial infarction in 12 patients (43%), unstable
angina in 14 (50%), and asymptotic in 2 (7%). Mean time to LTO was 5.4 6 3.2 months in
the irradiated group versus 4.5 6 2.1 in placebo patients (p 5 NS). The overall rate of
restenting for the entire study group at the time of radiation was 48.6%. Importantly, new
stents were placed in 82% of the irradiated and in 100% of the placebo patients who presented
with LTO. Multivariate analysis determined that new stenting was the main predictor of
LTO.
CONCLUSIONS Intracoronary radiation for patients with in-stent restenosis is associated with a high rate of
LTO. Restenting may contribute late thrombosis. Prolonged antiplatelet therapy (up to six
months) should be considered for these patients. (J Am Coll Cardiol 2000;36:65–8) © 2000
by the American College of Cardiology
Vascular brachytherapy is effective in preventing restenosis.
Preclinical studies utilizing both beta and gamma emitters
have shown a reduction of smooth muscle proliferation,
prevention of late contraction, and a delayed healing re-
sponse following vascular injury (1–4).
An important clinical application of vascular brachyther-
apy is as adjunct therapy for the treatment of in-stent
restenosis. Several studies, including three randomized
trials, have shown a reduction in recurrent in-stent resten-
osis of 50% to 70% compared to conventional therapy (5–9).
However, radiation has been reported to induce thrombosis.
Previous studies on the vascular effects of external beam
radiation have suggested that increased thrombosis is a
complication of delayed healing (10,11).
Thrombotic occlusion following balloon angioplasty usu-
ally occurs either immediately or within 24 hours following
intervention. Stents are more often associated with subacute
thrombosis (within 30 days of implantation), which is well
controlled using antiplatelet therapy for 15 days (12–15).
Among the complications associated with vascular brachy-
therapy is a new phenomenon of late coronary thrombosis
(.30 days) (16,17).
The purpose of the current study was to determine the
rate of late total occlusion (LTO) following brachytherapy
for in-stent restenosis as well as its clinical presentation and
predictors.
METHODS
From February 1997 to December 1998, a total of 473
patients with in-stent restenosis at the Washington Hospi-
tal Center were enrolled into six randomized vascular
brachytherapy trials—WRIST (Washington Radiation for
In-Stent restenosis Trial), LONG WRIST (long in-stent
restenosis lesions 36 to 80 mm), SVG WRIST (in-stent
restenosis in vein grafts), GAMMA-1, ARTISTIC (An-
giorad Radiation Therapy for In-Stent restenosis Trial in
Coronaries), PREVENT (Proliferation Reduction with
Vascular Energy Trial)—and into two registries, BETA
WRIST (beta radiation for in-stent restenosis) and LONG
WRIST HIGH DOSE (long lesions 36 to 80 mm using
15 Gy at 2.4 mm at the perspiration point). All clinical trials
were approved by the Food and Drug Administration and
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by the Institutional Review Board and the radiation safety
committee at the Washington Hospital Center. All patients
signed consent forms before enrollment and completed at
least six months of clinical and angiographic follow-up.
The description of trials, the isotope, and the dose are
displayed in Table 1. The protocols had similar inclusion
criteria including in-stent restenosis with a diameter steno-
sis (DS) .50%, in vessels 2.5 to 5.0 mm in diameter, a
lesion length up to ,80 mm, and successful primary
intervention by balloon, ablation (laser or rotational atherec-
tomy), restenting, or the combination with a ,30% residual
DS without complications. The main exclusion criteria were
patients with acute myocardial infarction (MI) ,72 hours
previously, a left ventricular ejection fraction ,20%, prior
irradiation treatment to the chest, evidence of thrombus by
angiogram, and multiple lesions in the same vessels.
Typically, focal lesions (,10 mm in length) were ap-
proached with balloon dilation, and diffuse lesions
($10 mm in length) underwent ablation using excimer laser
angioplasty or rotational atherectomy. Restenting was per-
formed in 41% of patients when necessary to optimize the
primary angiographic results, to cover the entire lesion
length (especially when the in-stent restenosis process
extended beyond the length of the stent) or to treat edge
dissections. In preparation for the radiation treatment the
activated clotting time (ACT) was monitored and adjusted
with heparin to exceeded 300. The source was delivered per
protocol and left in place for a sufficient time to deliver the
assigned dose. Cinefluoroscopy was used to verify catheter
and source position.
Following radiation procedure, a final angiogram was per-
formed and further balloon dilation or stent implantation was
performed if the angiographic result had deteriorated signifi-
cantly (.30% DS). The femoral sheaths were removed at the
day of the procedure and patients received routine after-
angioplasty care including ticlopidine 250 mg twice daily or
clopidogrel 75 mg daily for one month and aspirin 325 mg
daily. Gamma-1 patients who underwent restenting were
instructed to continued ticlopidine for two months.
All patients completed clinical and angiographic
follow-up at six months after enrollment. Quantitative
coronary angiographic (QCA) analysis was performed using
automated edge-detection algorithm. Selected end-diastolic
cineframes were optically magnified (2.4:1) and digitized
using a cine-video converter. Using the contrast filled
catheter as the calibration standard, minimal lumen diam-
eter (MLD), reference diameter, and percent diameter
stenosis (DS) pre- and postintervention were measured. For
the purpose of the current analysis, subacute thrombosis was
defined as angiographically documented total occlusion #30
days; and LTO was defined as angiographically documented
total occlusion .30 days’ postintervention. The LTO was
applied for patients who had patent artery at six months’
follow-up and presented with total occlusion of the same
site at a later time.
The time to LTO and the relevant clinical event associ-
ated with LTO were recorded and adjudicated. Several
approaches were used to treat the LTOs including throm-
bolytics (5 patients), thrombectory (Angioget, Possis Med-
ical, Minneapolis, Minnesota), PTCA (percutaneous trans-
luminal coronary angioplasty) (14 patients), coronary artery
bypass surgery (7 patients), and conservative medical ther-
apy (7 patients); these treatment choices were not mutually
exclusive.
Statistical analysis. Data were recorded prospectively and
forwarded to the data-coordinating center. The results are
expressed as mean 6 1 SD. Continuous variables were com-
pared using unpaired, two-tailed Student t test. Categorical
values were compared using chi-square or the Fisher exact test.
P values ,0.05 were considered statistically significant. Mul-
tivariate logistic regression analysis to determine the predictors
of late thrombosis included demographic, morphological and
Abbreviations and Acronyms
ACT 5 activated clotting time
DS 5 diameter stenosis
LTO 5 late total occlusion
MI 5 myocardial infarction
MLD 5 minimal lumen diameter
PTCA 5 percutaneous transluminal coronary
angioplasty
QCA 5 quantitative coronary angiographic
WRIST 5 Washington Radiation for In-Stent resteno-
sis Trial
Table 1. Rate of Late Total Occlusion by Studies, Emitters, and Doses
Study Emitter Dose (Gy)
Late Total Occlusion Rate
Treated Control
WRIST Ir-192 15 at 2 mm 10/104 (9.6%) 2/65 (3.1%)
GAMMA-1 Ir-192 8–30 by IVUS 3/20 (15%) 0/20 (0%)
ARTISTIC Ir-192 15 at 2 mm 2/24 (8.3%) 0/8 (0%)
SVG WRIST Ir-192 15 at 2 mm 1/27 (3.7%) 0/27 (0%)
LONG WRIST Ir-192 15 at 2 mm 4/45 (8.8%) 0/45 (0%)
High-dose WRIST Ir-192 15 at 2.4 mm 2/29 (6.9%) p
BETA WRIST Y-90 20.6 at 1 mm 4/49 (8.1%) p
PREVENT P-32 20–24 at 1 mm 2/10 (20.0%) 0/5 (0%)
TOTAL All Any 28/308 (9.1%) 2/165 (1.2%)
*Registries in which all patients received radiation.
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clinical variables. Logistic regression is widely used to fit
models for binary or ordinal, multicategorical variables. We
entered all clinically relevant variables in the model, and then
backward selection method was used to find predictors of the
outcome. We used a level of 0.05 as a cut-off point to let the
predictors stay in the model.
RESULTS
Of the 473 patients entered into the various trials, 308
patients were treated with active radiation and 165 were
treated with placebo. Subacute thrombosis occurred in three
(0.9%) patients treated with radiation and in none of the
placebo-treated patients. Late total occlusion occurred in 28
patients treated with radiation (9.1%), but in only 2 placebo
patients (1.2%, p , 0.0001). Late late total occlusion
occurred in two patients (0.6%) treated with radiation and
none of the placebo patients. The rate of LTO did not vary
significantly across protocols, emitters, and dosage. The
clinical, angiographic, and procedural details of the 28
patients who received radiation to treat in-stent restenosis
and who presented with LTOs are shown in Table 2. The
mean time to LTO was 5.5 6 3.1 months, with the majority
of the 24 patients presenting between two and seven
months. Late LTO occurred in two patients at 12 and 18
months despite absence of pathology on a six-month an-
giographic follow-up. The LTO was associated with acute
MI in 12 (43%) of the patients and unstable angina in 14
(50%) patients; only 2 (7%) LTO patients were asymptom-
atic; in these patients total occlusions were found at routine
six-month follow-up. The LTO from the irradiated group
was treated: medically, 9 patients; repeat angioplasty, 14
patients; bypass surgery, 5 patients. There were three deaths
among the patients who presented with LTO, one death
from the medically treated group, one postbypass surgery,
and one following angioplasty. The two patients with total
occlusion from the placebo group were crossed over to
radiation therapy and presented with patent artery at six
months.
Restenting as part of the treatment of in-stent restenosis
was performed in 230 of 473 (48.6%) patients. Importantly,
22 of the 28 irradiated patients (79%) who subsequently
presented with LTO had a new stent placed during the
treatment of in-stent restenosis. The LTO rate among
patients who received stents and radiation was 14.6%. The
rate of LTO in the patients who were treated with radiation,
but no new stenting, was 6 of 157 (3.8%).
Multivariate logistic regression analysis was performed
for the patients in the various WRIST studies. We specif-
ically entered the following variables into the model: gender,
diabetes, lesion length, reference vessel diameter, lesion
length, final lumen diameter, beta radiation gamma radia-
tion, and additional stenting. New stenting (odds ratio
[OR] 5 2.55, 95% confidence interval [CI] 5 1.0–5.1, p 5
0.04), and long lesions (OR 5 1.15, CI 5 1.0–1.2, p 5
0.04) were found to be the predictors for late thrombosis.
DISCUSSION
In the current study we report a high rate of LTOs in
patients undergoing radiation therapy to prevent recurrent
in-stent restenosis. Although some of these LTOs may be
the result of excessive tissue proliferation and exaggerated
in-stent restenosis, the clinical and angiographic features
suggest that the main etiology for LTO for this cohort is
thrombus formation. Late thrombosis following coronary
intervention and vascular brachytherapy is a new phenom-
enon. Because late thrombosis is rarely seen following
conventional intervention, the cases of late thrombosis in
the current study should be attributed to the use of radiation
therapy.
Mechanisms. We have previously reported a correlation be-
tween the radiation dose and the thrombosis rate in the porcine
model (18). Our findings suggested that healing response in
irradiated arteries is delayed and that this delay may promote
thrombus formation—especially in stented arteries with im-
paired re-endothelialization. In the current study, LTO was
manifest as late closure and was found irrespective to the type
of the radiation (beta versus gamma) or the prescribed dose to
the vessel wall or the adventitia. Salame et al. (19) observed
platelet recruitment at the irradiated injured site in porcine
coronaries at 28 days. Previous studies on the vascular effects of
external beam radiation have suggested that increased throm-
bosis is an adverse late healing effect (10,11). Furthermore,
thrombi present in irradiated arteries tend to be acellular, with
an absence of macrophages and lymphocytes thought to be
involved in the repair mechanism. Decreased numbers or
impaired function of macrophages may prolong the residence
of the thrombus and its components (platelets and fibrin) at the
injured segment and may delay its organization. Our animal
Table 2. Clinical, Procedural, and Angiographic Findings in 28
Patients Who Received Brachytherapy for In-stent Restenosis
and Who Presented With Late Total Occlusion
Demographics
Age (yrs) 58.0 6 11.4
Gender (male) 67.8
Number of in-stent restenosis episodes 2.3 6 1.5
Angiographic findings preintervention
Reference (mm) 2.44 6 0.34
Minimal luminal diameter (mm) 0.76 6 0.37
Diameter stenosis (%) 76 6 15
Device used to treat in-stent restenosis*
Balloon 8 (28.6%)
Rotational atherectomy 12 (42.8%)
Excimer laser angioplasty 8 (28.6%)
Restenting 23 (82.1%)
Angiographic findings postintervention
Minimal luminal diameter (mm) 2.05 6 0.42
Diameter stenosis (%) 26 6 9
Clinical presentation of late total occlusion
Time to late total occlusion (months) 5.4 6 3.2
Acute MI 12 (42.8%)
Recent onset unstable angina 14 (50.0%)
Asymptomatic 2 (7.2%)
*Not mutually exclusive.
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studies showed that thrombosis is related more to the total
dose at the adventitia rather than to the luminal surface (18).
Recent studies examining human carotid arteries that were
exposed to external radiation have demonstrated impaired
endothelium with reduction of nitric oxide production, which
can potentially result in thrombosis (20).
Predictors of late thrombosis. In the current study, late
thrombosis occurred mainly in patients who underwent new
stent implantation at the time of brachytherapy. Conversely,
the late thrombosis rate in patients who did not receive a
new stent at the time of irradiation was similar to the
nonirradiated group. Restenting an in-stent restenosis le-
sion has been advocated as one approach to this clinical
problem. While it achieves the largest acute lumen dimen-
sions, the long-term recurrence rate may be similar to other
nonbrachytherapy techniques.
There are a number of potential explanations for late
thrombosis in the setting of new stent implantation. First,
small dissections can occur at the stent edges of newly
implanted stents. Radiation may delay the healing of these
edge dissections, which may remain thrombogenic. In a
recent study using beta radiation, it was found that 7 of 16
(45%) dissections in unstented arteries remained unhealed
at six-month follow-up (21). Second, incomplete, delayed,
or impaired re-endothelialization may contribute to the
initiation of a thrombus. Although the majority (26/28) of
late thromboses occurred between two and seven months
following irradiation, two patients had documented patency
at six months and presented with “late late total occlusion”
at 12, and 18 months. The “late LTOs” may be related to
regression or erosion of tissue outside the stent. This may
leave the stent unopposed to the vessel wall and serve as a
nidus for thrombosis.
Conclusions. Our study clearly demonstrates a new com-
plication of intracoronary radiation for patients with in-
stent restenosis—late total occlusion. This phenomenon is
more pronounced after restenting, but not after radiation
and no new stenting.
These findings suggest that patients treated with stenting
and radiation should be placed on prolonged antiplatelet
therapy; we suggest a duration of at least six months.
However, it is possible that prolonged antiplatelet therapy
will only delay late thrombosis. If this occurs, increasing the
rate of “late LTO,” antiplatelet therapy will be required for
longer than six months or other agents that may enhance
the healing response and the re-endothelialization of new
stents placed in irradiated arteries. Further, restenting
should be avoided unless absolutely necessary, and the use of
heparin-coated stents may be beneficial.
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